Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

3(42.9%)

Phase 1

2(28.6%)

Phase 3

2(28.6%)

7Total

Phase 2(3)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02000219Phase 2Completed

Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis

Role: lead

NCT03116685Phase 3Completed

A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Role: lead

NCT03938272Phase 3Terminated

An Extension Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria

Role: lead

NCT02012985Phase 1Completed

Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria

Role: lead

NCT00638703Phase 2Completed

Study to Evaluate the Efficacy and Safety of OxabactTM on Reduction of Urinary Oxalate in Primary Hyperoxaluria Patients

Role: lead

NCT01037231Phase 2Completed

Phase 2/3 Oxabact Study

Role: lead

NCT01127087Phase 1Completed

Oxazyme in Patients With Hyperoxaluria

Role: collaborator

All 7 trials loaded